FDA Panel: Heart Closure Device Safety Data Demands Further Study
This article was originally published in The Gray Sheet
Executive Summary
More study is required to make sense of the adverse event rates associated with two marketed atrial septal defect occluders, a May 24 FDA panel concluded. St. Jude Medical, in particular, should start a new prospective study for its Amplatzer device, the panel recommends.
You may also be interested in...
Case Closed On PFO Closure? A Principal Investigator Weighs In
Future prospects for devices that close patent foramen ovale heart defects to prevent recurrent strokes remain in some doubt as researchers continue to mull recent data.
AGA Purchase Gives St. Jude Structural Heart Leadership, Growth Potential
St. Jude Medical will become the market leader in structural heart defect closure devices with its planned $1.3 billion purchase of AGA Medical.
Finding The Sweet Spot For Real-World Evidence: Aetion Stresses Early Feasibility Assessment
Robust natural history data sets with well-chosen outcomes are fundamental in Aetion’s regulatory feasibility tool for real-world evidence, built through analysis of US FDA case studies and guidance.